Navigation Links
MabVax Therapeutics Closes $5.25 Million Financing with Numoda Capital Innovations, Burrill Capital Fund IV, and RTP Venture Fund
Date:11/20/2012

SAN DIEGO, Nov. 20, 2012 /PRNewswire/ -- MabVax Therapeutics, Inc., a privately held clinical stage biotechnology company focused on the development of proprietary immunotherapies to address the unmet medical need of preventing recurrent cancer, today announced the closing of the first tranche in their Series B financing.  Numoda Capital Innovations led the round and was joined by existing investors Burrill Capital Fund IV and RTP Venture Fund for an aggregate investment of $5.25 million. The additional capital will allow MabVax to continue the development of its phase 2 vaccine aimed at preventing recurrent sarcoma and its 5B1 antibody program targeting metastatic pancreatic cancer.

The phase 2 clinical trial of the sarcoma vaccine has reached the targeted enrollment of 134 stage IV sarcoma patients in a randomized, multicenter, double-blind study of a vaccine specifically developed to elicit a targeted antibody response intended to kill residual circulating cancer cells and micrometastases that can cause recurrent sarcoma. The primary efficacy result of progression free survival (PFS) is expected to be reported in the second half of 2013.  The financing provides MabVax access to Numoda's advanced and patented clinical trial information technologies and management systems. These technologies will enable MabVax to move through the clinical trial process efficiently while providing visibility for reporting early assessments and timely trial results.  

The financing will also allow MabVax to continue development of the 5B1 antibody program targeting an antigen that is widely expressed in pancreatic cancer. The company has discovered and completed preclinical testing of a fully human IgG1 antibody with high affinity and exquisite specificity for the antigen and remarkable in vivo efficacy in a series of pancreatic and other cancer cell lines in SCID mice. MabVax is planning to begin GMP manufacturing of this antibody early in 2013
'/>"/>

SOURCE MabVax Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Cystic Fibrosis Foundation Therapeutics Announces $58 Million CF Drug Discovery Agreement with Pfizer
2. Echo Therapeutics Hires Daniel Sunday as Vice President of Manufacturing and Global Supply Chain
3. Caliber and ImmunGene Launch Valor Biotherapeutics, a Joint Venture to Develop Antibody-Interferon Fusion Therapeutics to Treat Cancers
4. Echo Therapeutics Chosen to Present at the 12th Annual Diabetes Technology Meeting
5. Immunomic Therapeutics Begins Phase I Japanese Red Cedar JRC-LAMP-Vax Vaccine Safety Study
6. Stemline Therapeutics Lead Clinical Candidate SL-401 Induces a Complete Response in a Patient with a Drug-Refractory Plasmacytoid Dendritic Cell Neoplasm
7. Echo Therapeutics Announces Third Quarter 2012 Financial Results
8. Orexigen Therapeutics Reports Financial Results for the Third Quarter Ended September 30, 2012
9. Particle Sciences Develops Novel Ocular Formulation for Eyeon Therapeutics
10. Halozyme Therapeutics To Present At The Lazard Capital Markets 9th Annual Healthcare Conference
11. Novelos Therapeutics Closes $2 Million Private Placement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... BioElectronics Corporation (OTC Pink: BIEL), the ... medical devices, announced today that its registry study ... device has been published in the prominent peer ... http://www.futuremedicine.com/doi/full/10.2217/PMT.15.35 .  More than 5,000 chronic pain sufferers ... Chronic pain is a major ...
(Date:8/4/2015)... , Aug. 4, 2015  ContraVir Pharmaceuticals, Inc. ... on the development and commercialization of targeted antiviral ... Executive Officer, will present live at VirtualInvestorConferences.com on ... 6, 2015 TIME: 12:15PM EDT LINK: http://tinyurl.com/aug6-pre-ctrv ... live, interactive online event where investors are invited ...
(Date:8/4/2015)... Wis. , Aug. 4, 2015  Ironshore ... agreement with Restore Health, a company specializing in ... a double-blind clinical trial, designed to evaluate the ... in development to treat Attention-deficit/hyperactivity disorder (ADHD). This ... Restore Health originally partnered with Ironshore ...
Breaking Medicine Technology:BioElectronics' Landmark 5,000+ Chronic Pain Patient Study Published in Pain Management Medical Journal 2ContraVir to Webcast Investor Presentation on August 6: VirtualInvestorConferences.com 2ContraVir to Webcast Investor Presentation on August 6: VirtualInvestorConferences.com 3Restore Health Secures Another Clinical Trial with Ironshore Pharmaceuticals & Development 2
... Pharmaceuticals, Inc. (NYSE: WPI ), a leading ... President and Chief Executive Officer, will provide an overview ... Piper Jaffray Health Care Conference on Wednesday, November 30, ... Palace Hotel in New York. The presentation will be ...
... Nov. 21, 2011 Reportlinker.com announces that a ... catalogue: The 2011 Vibrio Diagnostics ... Forecasts by Country http://www.reportlinker.com/p0444741/The-Vibrio-Diagnostics-Market-US-Europe-JapanTest-Volume-and-Sales-Forecasts-by-Country.html ... detailed analysis of the Vibrio diagnostics market in ...
Cached Medicine Technology:The 2011 Vibrio Diagnostics Market: US, Europe, Japan Test Volume and Sales Forecasts by Country 2The 2011 Vibrio Diagnostics Market: US, Europe, Japan Test Volume and Sales Forecasts by Country 3The 2011 Vibrio Diagnostics Market: US, Europe, Japan Test Volume and Sales Forecasts by Country 4
(Date:8/4/2015)... Angeles, CA (PRWEB) , ... August 04, 2015 , ... ... study that found financial incentives to be a viable method for encouraging people to ... wager money on the future of their weight loss success, adding a financial incentive ...
(Date:8/4/2015)... (PRWEB) , ... August 04, 2015 , ... ... suffering from underarm sweat. Evolutions Medical & Day Spa in Santa Barbara, CA ... only non-invasive, FDA cleared treatment that permanently eliminates sweat and odor glands in ...
(Date:8/4/2015)... (PRWEB) , ... August 04, 2015 , ... ... of Local Food,” scheduled for Nov. 3 – 4, 2015, at UC San ... sustainably, create new businesses, improve food access, and manage resources efficiently against the ...
(Date:8/4/2015)... ... 04, 2015 , ... Members receiving care from a doctor who participates in ... that is nine percent lower -- than those members at traditional doctor practices, according ... programs. , “The promise of patient-centered, or value-based, care to deliver better quality ...
(Date:8/4/2015)... ... August 04, 2015 , ... Increasingly, patients are researching online ... physician. In an effort to share more and better information with these savvy ... publicly share patient satisfaction ratings and comments about its doctors and advanced practice ...
Breaking Medicine News(10 mins):Health News:Article on Incentivizing Weight Loss Mirrors Similar Motivations Surrounding Weight Loss Surgery, Says Dr. Feiz & Associates 2Health News:Simple, Non-Invasive, Permanent Solution To Stop Underarm Sweating in Santa Barbara 2Health News:Simple, Non-Invasive, Permanent Solution To Stop Underarm Sweating in Santa Barbara 3Health News:Diversity of Urban and Hydroponic Farms of the Future to Highlight Seedstock Annual Conference Field Trip 2Health News:Diversity of Urban and Hydroponic Farms of the Future to Highlight Seedstock Annual Conference Field Trip 3Health News:Horizon BCBSNJ: 2014 Results Show Patient-Centered Care Continues to Deliver on Promise of Better Quality Care at a Lower Cost 2Health News:Horizon BCBSNJ: 2014 Results Show Patient-Centered Care Continues to Deliver on Promise of Better Quality Care at a Lower Cost 3Health News:UPMC 1st in Pa. to Share Provider Ratings 2Health News:UPMC 1st in Pa. to Share Provider Ratings 3
... you are pregnant, here,s another reason to work out: ... developing neurodegenerative diseases, such as Alzheimer,s, later in life. ... FASEB Journal ( http://www.fasebj.org ) shows that mice ... Alzheimer,s disease showed fewer signs of the disease and ...
... of the leading causes of death and morbidity worldwide, ... 2008, the worldwide cost of cancer due to premature ... to be US$895 billion. An expert report from ... of some of the world,s leading cancer specialists, from ...
... Netherlands: Mothers who are exposed to particular agents during pregnancy ... asthma, according to new research. The study will ... Society,s Annual Congress in Amsterdam. It is ... and chemicals it can cause asthma. However, there has been ...
... The Netherlands: A new study has shown that people ... reduced lung function are at a serious risk of ... presented today (26 September 2011) at the European Respiratory ... COPD and reduced lung function should be routinely screened ...
... and unspoken clues exchanged by patients and doctors exert ... study by the University of Michigan Health System. Researchers ... interviews with participants to help elucidate signals sent and ... The method shows promise for improving medical decision ...
... of personalised medicine, gains in cancer survival over the ... trials with less stringent evidence criteria, a researcher told ... 26 Sept). The introduction of targeted treatments means ... most effective way of getting new treatments to cancer ...
Cached Medicine News:Health News:Pregnant women who exercise protect their offspring against long-term neurodegenerative diseases 2Health News:Unequal access to cancer care can no longer be tolerated 2Health News:Unequal access to cancer care can no longer be tolerated 3Health News:A mother's occupation while pregnant can cause asthma in children 2Health News:New evidence highlights risk of comorbidities for COPD patients 2Health News:Non-verbal clues guide doctor-patient relationships, clinical judgments, U-M study finds 2Health News:Non-verbal clues guide doctor-patient relationships, clinical judgments, U-M study finds 3Health News:Smaller, faster trials can improve cancer patient survival 2Health News:Smaller, faster trials can improve cancer patient survival 3
BD Beaver implant blade, 5.1 mm, angled 45, bevel up. matte finish. Designed for widening the incision for lens implantation. Beaver implant blades put precision and control in your hands, sterile....
BD Beaver Sickle Edge blade, straight, 5.0 mm W x 84 mm long. Specially designed for superior visibility and easy access into the ear canal, sterile....
BD Beaver Meniscus blade, 7 mm flat (4/bx, 1 bx/ca), specially designed maximum leverage and visibility, cutting edge: 7 mm, sterile....
RM-1970 Mucotome ergonomic design with E-Type coupling, designed for mucosal repair surgery....
Medicine Products: